FDA grants accelerated approval to Bristol Myers Squibb’s Breyanzi for follicular lymphoma
Bristol Myers Squibb (NYSE: BMY) has announced a significant breakthrough in the treatment of follicular lymphoma with the U.S. Food and Drug Administration (FDA) granting ... Read More
BeiGene’s BRUKINSA gains accelerated FDA approval for follicular lymphoma treatment
In a significant development for patients with relapsed or refractory follicular lymphoma, BeiGene, Ltd. has announced the U.S. Food and Drug Administration (FDA) has granted ... Read More